China approves edaravone for ALS
Last updated: 01 November 2019
This is a summary of an article in ALS News Today.
China's regulatory agency, the National Medical Products Administration, has approved the amyotrophic lateral sclerosis (ALS) therapy called edaravone (also known by the brand names Radicava, Radicut, among others). This treatment will be sold in China by a subsidiary of the medicine's developer, Mitsubishi Tanabe Pharma Corporation.
Radicut/Radicava (edaravone) is meant to slow the progression of ALS. Sold in the United States under the name Radicava, in 2017 it became the first ALS treatment approved by the U.S. Food and Drug Administration (FDA) in over 20 years.
This medicine is currently available for administration intravenously at home or in a clinic. However, the manufacturer is looking into the development of an oral formulation.
Ana Pena. China Becomes 6th Country to Approve Edaravone Infusion Therapy for ALS. ALS News Today. 12/08/2019